Press Release

Bradenton Research Center announced that it is actively recruiting subjects for a global Phase III clinical trial named GRADUATE. The study will assess how safe and effective an investigational drug is at slowing the progression of early Alzheimer’s disease. Dr. W. Alvin McElveen, Principal Investigator, states “At Bradenton Research Center, we take great pride in our commitment to serving people living with Alzheimer’s disease. This clinical study is an important step to helping us find meaningful options for those impacted.”

About Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurological disorder that causes memory loss and behavior disturbances that eventually result in a person’s inability to perform daily activities. An estimated 5.7 million Americans have Alzheimer’s disease. Evidence suggests pathophysiological changes typically begin years prior to the symptoms that lead to a clinical diagnosis. There are currently no approved medications that can slow or stop the progression of Alzheimer’s disease – only medications that temporarily lessen secondary symptoms (like memory loss and anxiety) in some people with more advanced Alzheimer’s disease.

More about Bradenton Research Center

Bradenton Research Center was founded in 1992 to offer patients hope of better treatments than those already available. The site has successfully completed over 150 clinical trials. For more information, please call the Center at (941)708-0005 or visit